GlassScriptPhysician profile
Alan Thomas Chang
NPI 1699784934
$3,435.52
in general payments reported to CMS, 2019-2025
36 companies · $757 in 2025
The $757 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $355 · 2020: $114 · 2021: $269 · 2022: $330 · 2023: $795 · 2024: $817 · 2025: $757.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,368.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $393.84 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $376.30 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $341.41 | 2020-2025 | Airsupra, Farxiga |
| Amgen INC. | $328.31 | 2020-2024 | Repatha, Otezla |
| Janssen Biotech, INC. | $255.25 | 2024-2025 | Tremfya, Stelara, Simponi |
| Pfizer INC. | $228.72 | 2019-2025 | |
| Novo Nordisk INC | $195.24 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $143.16 | 2023 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.26 | 2021-2024 | Spiriva Respimat |
| Neurocrine Biosciences, INC. | $121.84 | 2025 | |
| Medtronic, INC. | $107.05 | 2022 | |
| Acclarent, INC | $90.08 | 2019 | |
| Abbott Laboratories | $73.57 | 2023-2024 | Freestyle Libre 3, Octrode, Freestyle Libre 2 |
| Exact Sciences Corporation | $53.59 | 2024-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $48.33 | 2019 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.